Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

Jesús F. San Miguel, Katja Weisel, Philippe Moreau, +22

The Lancet Oncology

Hematological MalignancyMedicineHematologyMyeloid NeoplasiaPharmacotherapy +4

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar, +123

The Lancet

Hematological MalignancyMedicineImmunologyHematologyPharmacotherapy +4

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Philippe Moreau, Meletios Α. Dimopoulos, Joseph Mıkhael, +82

The Lancet

Hematological MalignancyRelapsed Multiple MyelomaMedicineRandomised Phase 3Immunology +9

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Meletios Α. Dimopoulos, Evangelos Terpos, Mario Boccadoro, +69

The Lancet Oncology

Hematological MalignancyOncologyDexamethasone Versus PomalidomideMetronomic TherapyImmunology +5

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

Saad Z. Usmani, Alfred L. Garfall, Niels W.C.J. van de Donk, +18

The Lancet

Hematological MalignancyMedicineMalignant Blood DisorderImmunologyTumor Immunity +6

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, +117

The Lancet Haematology

Hematological MalignancyOncologyHematologyImmunologyImmune Checkpoint Inhibitor +4

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Saad Z. Usmani, Fredrik Schjesvold, Albert Oriol, +114

The Lancet Haematology

Hematological MalignancyMedicineImmunologyClinical TrialsHematology +5

Multiple myeloma: practice patterns across Europe

Marc S. Raab, Michèle Cavo, Michel Delforge, +9

British Journal of Haematology

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results

Xavier Leleu, Lionel Karlin, Margaret Macro, +31

Blood

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience

Benjamin Hebraud, Florence Magrangeas, Alice Cleynen, +22

Blood